Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R2 | O00459 | 11/20 | 0.67 |
| ▸ | PIK3C2B | O00750 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19989071 | 0.93 | PIK3R2 (0.69) | PIK3R2PIK3C2BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19989425 | 0.90 | PIK3R2 (0.65) | PIK3R2PIK3C2BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19989228 | 0.89 | PIK3R2 (0.67) | PIK3R2PIK3C2BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19989243 | 0.86 | PIK3R2 (0.65) | PIK3R2PIK3C2B | |
| SCHEMBL19988898 | 0.82 | PIK3R2 (0.69) | PIK3R2PIK3C2BMAPTPKMKDM4E | |
| SCHEMBL20000188 | 0.80 | PIK3R2 (0.80) | PIK3R2 | |
| SCHEMBL20000160 | 0.80 | PIK3R2 (0.78) | PIK3R2 | |
| SCHEMBL19989530 | 0.79 | PIK3R2 (0.65) | PIK3R2PIK3C2BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19988985 | 0.79 | PIK3R2 (0.67) | PIK3R2PIK3C2BPKM | |
| SCHEMBL19988980 | 0.78 | PIK3R2 (0.59) | PIK3R2PIK3C2BMAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086747-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| WO-2018057808-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086747-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, TNNI3K | PIK3R2 18/4885PIK3C2B 20/4885CYP1A2 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.